th 7

BARNES & THORNBURG

JAN 2 9 2002 E

11 South Meridian Street Indianapolis, Indiana 46204 (317) 236-1313

NATHE UNFIED STATES PATENT AND TRADEMARK OFFICE

Group:

Confirmation No.:

2859

Application No.:

09/762,224

Invention:

Pseudotyped Retroviruses And

Stable Cell Lines For Their

Production

Applicant:

David A. Sanders, et al.

Filed:

August 4, 1999

Attorney Docket:

3220-69199

Examiner:

John L. Anderson

Certificate Under 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Weshington DC 20231

Washington, D.C. 20231

on January 7, 2002

(Signature)

Garla L. Twyman (Printed Name)

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Ì

This is in response to the Notification of Defective Response mailed December 7, 2001 for which the one month shortened statutory period for response is set to expire on January 7, 2002. Applicants believe no fee is due with this response. If any fees are required, the Assistance Commissioner is hereby authorized to charge the same to Deposit Account No. 10-0435, with reference to our matter 3220-69199.

Please consider the following amendments and remarks:

IN THE SPECIFICATION

Please amend the specification as follows:

On page 29, line 28, after "-3;)", please insert -- (SEQ ID NO:7) ---;

On page 29, line 29, after "-3')", please insert -- (SEQ ID NO:8) --; On page 29, line 30, please delete "SEQ ID 1" and replace it with -- SEQ ID NO:1--; On page 29, line 31, please delete "SEQ ID 1" and replace it with -- SEQ ID NO:1--; On page 30, line 9, please delete "SEQ ID 1 also" and replace it with -- SEQ ID NO:2--; On page 37, line 20, please delete "SEQ ID 2" and replace it with -- SEQ ID NO:3--; On page 37, line 22, please delete "SEQ ID 2" and replace it with -- SEQ ID NO:3--; On page 29, line 26, please delete "SEQ ID 2 also" and replace it with -- SEQ ID NO:4--; On page 40, line 30, please delete "SEQ ID 3" and replace it with -- SEQ ID NO:5--; On page 41, line 1, please delete "SEQ ID 3 also" and replace it with -- SEQ ID NO:6--.

IN THE SEQUENCE LISTING:

Please delete the sequence listing and replace it with a substitute sequence listing submitted herewith.

REMARKS

Applicants have deleted the sequence listing and have submitted an amended substitute sequence listing herewith. In compliance with 37 C.F.R. §1.821(e), Applicants have also submitted a computer readable form of the sequence listing, the content of which is identical to the enclosed paper copy of the sequence listing.

This submission of an amended sequence listing finds full support in the specification and adds no new matter. SEQ ID NOS:1-6 are identical to the nucleic acid and amino acid sequences of SEQ ID 1-3 of the original sequence listing. Corrections were made to the formatting and the numbering of either the nucleotides or amino acids in the sequence by

generating the substitute sequence listing using Patentin 3.1. No changes were made to the sequences themselves. Additionally, the sequences for the primers disclosed on page 29, lines 28-29 have been added as SEQ IS NOS:7-8.

Applicants thus submit that the amended sequence listing complies with the requirements for such a disclosure as set forth in 37 C.F.R. §1.821-§1.825. Should the Examiner have any questions or wish to discuss this matter, it is requested that the undersigned attorney be contacted at (317) 231-7244.

Respectfully submitted,

Barbara S. Gibbs, Ph.D.

Registration No. 44,708 Agent for Applicants

BSG:glt Indianapolis, Indiana 46204 (317) 231-7244 INDS02 BGIBBS 422261v1